However, little is known regarding whether the results of previous RCTs focusing on the advantage of SGLT2 inhibitors for FLD could be applicable to a broader range of patients with DM and MAFLD encountered in real-world clinical practice. The gene discussed is SLC5A2; the disease is diabetes mellitus.